• All
  • Primary Antibodies
  • Conjugated Antibodies for IF
  • Conjugated Antibodies for FC
  • Secondary Antibodies
  • Antibody Labeling KitsNew
  • ELISA Kits
  • IHC Kits
  • Magnetic Cell Separation Kits
  • Cytokines & Growth Factors
  • Neutralizing/activating Antibodies
  • Nanobody-based Reagents
  • Accessory Products and Kits
  • Fusion Proteins
×
×
Host
0
Species Reactivity
0
Species Reactivity
0
Conjugate
0
Conjugate
0
Compatible Species
0
Conjugate
0

ChromoTek FITC Plus-conjugated CTLA4 VHH

FITC-ctla targets CTLA4 in FC and IF applications and shows reactivity with Human samples.

Host/Type

Alpaca VHH

Reactivity

Human

Applications

FC, IF

Conjugate

FITC Plus Fluorescent dye

Cat No : FITC-ctl

Synonyms

CTLA4-Nanobody, CTLA4-Single domain antibody (sdAb), CD152, Cytotoxic T-Lymphocyte-associated antigen 4, CTLA4, CTLA-4

Validation Data Gallery

  • 1X10^6 HEK CTLA4 transient transfected cells (red) and HEK parental cells were surface stained with 0.5 µg FITC Plus conjugated-CTLA4 VHH (FITC-ctl). Cells were not fixed.

    1X10^6 HEK CTLA4 transient transfected cells (red) and HEK parental cells were surface stained with 0.5 µg FITC Plus conjugated-CTLA4 VHH (FITC-ctl). Cells were not fixed.

  • Left: 1x10^6 PHA-treated (3d) human PBMCs were surface stained with 1ug FITC Plus conjugated CTLA-4 VHH (FITC-ctl) and CL405 CD3 (CL405-65151). Right: 1x10^6 PHA-treated (3d) human PBMCs were surface stained with 1ug FITC Plus conjugated CTLA-4 VHH (FITC-ctl) (red) or unstained (blue). 1X10^6 untreated human PBMCs were surface stained with 1ug FITC Plus conjugated CTLA-4 VHH (FITC-ctl) (black dashed). Cells were treated with FC Receptor Block prior to staining. Cells were fixed and permeabilized using Transfripction Factor Staining Buffer Kit (PF00011). Lymphocytes were gated.

    Left: 1x10^6 PHA-treated (3d) human PBMCs were surface stained with 1ug FITC Plus conjugated CTLA-4 VHH (FITC-ctl) and CL405 CD3 (CL405-65151). Right: 1x10^6 PHA-treated (3d) human PBMCs were surface stained with 1ug FITC Plus conjugated CTLA-4 VHH (FITC-ctl) (red) or unstained (blue). 1X10^6 untreated human PBMCs were surface stained with 1ug FITC Plus conjugated CTLA-4 VHH (FITC-ctl) (black dashed). Cells were treated with FC Receptor Block prior to staining. Cells were fixed and permeabilized using Transfripction Factor Staining Buffer Kit (PF00011). Lymphocytes were gated.

  • Left: 1x10^6 PHA-treated (3d) human PBMCs were surface stained with 0.5ug FITC Plus conjugated CTLA-4 VHH (FITC-ctl) and CL750 CD3 (CL750-65151). Right: 1x10^6 PHA-treated (3d) human PBMCs were surface stained with 0.5ug FITC Plus conjugated CTLA-4 VHH (FITC-ctl) (red) or unstained (blue). 1X10^6 untreated human PBMCs were surface stained with 0.5ug FITC Plus conjugated CTLA-4 VHH (FITC-ctl) (black dashed). Cells were treated with FC Receptor Block prior to staining. Cells were not fixed. Lymphocytes were gated.

    Left: 1x10^6 PHA-treated (3d) human PBMCs were surface stained with 0.5ug FITC Plus conjugated CTLA-4 VHH (FITC-ctl) and CL750 CD3 (CL750-65151). Right: 1x10^6 PHA-treated (3d) human PBMCs were surface stained with 0.5ug FITC Plus conjugated CTLA-4 VHH (FITC-ctl) (red) or unstained (blue). 1X10^6 untreated human PBMCs were surface stained with 0.5ug FITC Plus conjugated CTLA-4 VHH (FITC-ctl) (black dashed). Cells were treated with FC Receptor Block prior to staining. Cells were not fixed. Lymphocytes were gated.

  • 1x10^6 PHA-treated (3d) human PBMCs were surface stained with CL405 CD3 (CL405-65151) then fixed and permeabilized and stained with 1ug FITC Plus conjugated CTLA-4 VHH (FITC-ctl). Right: 1x10^6 PHA-treated (3d) human PBMCs were fixed and permeabilized then stained with 1ug FITC Plus conjugated CTLA-4 VHH (FITC-ctl) (red) or unstained (blue). 1X10^6 untreated human PBMCs were fixed and permeabilized then stained with 1ug FITC Plus conjugated CTLA-4 VHH (FITC-ctl) (black dashed). Cells were treated with FC Receptor Block prior to staining. Cells were fixed and permeabilized using Transfripction Factor Staining Buffer Kit (PF00011). Lymphocytes were gated.

    1x10^6 PHA-treated (3d) human PBMCs were surface stained with CL405 CD3 (CL405-65151) then fixed and permeabilized and stained with 1ug FITC Plus conjugated CTLA-4 VHH (FITC-ctl). Right: 1x10^6 PHA-treated (3d) human PBMCs were fixed and permeabilized then stained with 1ug FITC Plus conjugated CTLA-4 VHH (FITC-ctl) (red) or unstained (blue). 1X10^6 untreated human PBMCs were fixed and permeabilized then stained with 1ug FITC Plus conjugated CTLA-4 VHH (FITC-ctl) (black dashed). Cells were treated with FC Receptor Block prior to staining. Cells were fixed and permeabilized using Transfripction Factor Staining Buffer Kit (PF00011). Lymphocytes were gated.

  • HeLa cells transfected with human CTLA-4 were immunostained with FITC Plus conjugated-CTLA4 VHH (FITC-ctl) (1:500, green). Nuclei were stained with DAPI (blue). Epifluorescence images were acquired with a 40x objective and post-processed. Comment: Immunostaining with FITC-ctl can be performed live or after formaldehyde fixation.

    HeLa cells transfected with human CTLA-4 were immunostained with FITC Plus conjugated-CTLA4 VHH (FITC-ctl) (1:500, green). Nuclei were stained with DAPI (blue). Epifluorescence images were acquired with a 40x objective and post-processed. Comment: Immunostaining with FITC-ctl can be performed live or after formaldehyde fixation.

Product Information

FITC-ctla targets CTLA4 in FC and IF applications and shows reactivity with Human samples.

ApplicationsFC, IF
ReactivityHuman
ConjugateFITC Plus Fluorescent dye
TypeNanobody
ClassRecombinant
HostAlpaca
Affinity22 nM
Molecular Weight14.005 kDa
FormLiquid
Excitation/Emission Maxima Wavelengths495 nm / 524 nm
RRIDAB_3101937
Storage Buffer500 mM NaCl, 10 mM HEPES pH 7.0, 5 mM EDTA, 0.09% sodium azide
Storage ConditionStore at -20°C
BackgroundCTLA-4, also known as CD152, belonging to the immunoglobulin superfamily, is primarily found on activated T cells and regulatory T cells (Tregs). CTLA-4 is closely related to the T-cell costimulatory CD28, and both molecules bind to B7-1 and B7-2 on antigen-presenting cells. CTLA-4 acts as a negative regulatory molecule of T-cell responses. Besides the full-length transmembrane form, CTLA-4 also exists in a truncated soluble form (sCTLA-4).

Documentation

SDS
SDS-Immuno-Oncology VHHs